A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)

Clinical Trial ID NCT00585195

PubWeight™ 139.78‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00585195

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 36.78
2 ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012 9.76
3 Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 8.64
4 Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014 6.95
5 Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011 6.69
6 Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010 6.28
7 Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013 3.42
8 MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011 3.27
9 CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011 3.00
10 Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012 2.66
11 Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012 2.47
12 Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol 2015 2.26
13 Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011 2.19
14 Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013 2.04
15 Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012 1.88
16 HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009 1.57
17 Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011 1.57
18 Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011 1.55
19 HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2010 1.50
20 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
21 Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012 1.45
22 Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 1.19
23 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
24 Targeting MET Amplification as a New Oncogenic Driver. Cancers (Basel) 2014 1.11
25 Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 2015 1.07
26 The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol 2011 1.05
27 Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol 2011 1.04
28 Targeting the HGF-cMET Axis in Hepatocellular Carcinoma. Int J Hepatol 2013 0.99
29 Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun 2015 0.99
30 Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 2013 0.97
31 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
32 Lung cancer in the era of precision medicine. Clin Cancer Res 2015 0.96
33 Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. J Cancer Res Clin Oncol 2014 0.95
34 A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis 2013 0.94
35 Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. Cancer Sci 2011 0.92
36 Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? Front Oncol 2014 0.92
37 c-Met as a Target for Personalized Therapy. Transl Oncogenomics 2015 0.92
38 Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014 0.92
39 Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. Br J Clin Pharmacol 2016 0.91
40 Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Onco Targets Ther 2015 0.90
41 Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2013 0.89
42 Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012 0.89
43 Crizotinib: A comprehensive review. South Asian J Cancer 2013 0.85
44 Targeting genomic alterations in squamous cell lung cancer. Front Oncol 2013 0.85
45 Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget 2015 0.83
46 Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 2016 0.83
47 ALK Inhibitors, a Pharmaceutical Perspective. Front Oncol 2012 0.82
48 The democratization of the oncogene. Cancer Discov 2014 0.81
49 Activated RET and ROS: two new driver mutations in lung adenocarcinoma. Transl Lung Cancer Res 2013 0.81
50 Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer 2015 0.80
51 Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer 2016 0.79
52 New targeted treatments for non-small-cell lung cancer - role of nivolumab. Biologics 2016 0.79
53 Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report. Oncol Lett 2014 0.78
54 The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol 2014 0.78
55 MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res 2012 0.78
56 Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines. Oncotarget 2015 0.78
57 Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. Onco Targets Ther 2015 0.77
58 Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. World J Clin Oncol 2015 0.76
59 ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget 2016 0.76
60 MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. Clin Cancer Res 2016 0.76
61 Has MET met its match? Ann Transl Med 2016 0.76
62 Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. Drug Des Devel Ther 2015 0.75
63 Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism. Cancer Sci 2016 0.75
64 MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval. Transl Lung Cancer Res 2015 0.75
Next 100